Sinco Pharmaceuticals Chairman Resigns, Triggering Temporary Governance Non-Compliance

Sinco Pharmaceuticals Holdings Ltd. ( (HK:6833) ) has provided an announcement.

Sinco Pharmaceuticals Holdings Limited announced that chairman and executive director Huang Xiangbin has resigned from his roles, including as chairman of the nomination committee and authorised representative, effective 30 April 2026 to focus on other commitments. Vice chairman and executive director Huang Zhijian has been appointed as the new authorised representative, while the company temporarily falls out of compliance with Hong Kong Listing Rule 3.27A because the nomination committee currently lacks a chairman, and the board has committed to filling the position within three months and issuing further updates.

The resignation is not due to any disagreement with the board, and Sinco’s directors expressed gratitude for Huang Xiangbin’s contributions and extended a warm welcome to Huang Zhijian in his expanded role. The governance gap around the nomination committee chair highlights a short-term compliance issue for the company, but management has pledged best efforts to restore full adherence to listing requirements promptly, a move closely watched by shareholders and regulators concerned with board oversight and corporate governance standards.

More about Sinco Pharmaceuticals Holdings Ltd.

Sinco Pharmaceuticals Holdings Limited is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange, operating in the pharmaceutical sector. The company is governed by a board comprising executive, non-executive and independent non-executive directors and is subject to Hong Kong Listing Rules for corporate governance and board committee structures.

Average Trading Volume: 213,363

Technical Sentiment Signal: Sell

Current Market Cap: HK$384.2M

For a thorough assessment of 6833 stock, go to TipRanks’ Stock Analysis page.